

S1 Table. Baseline characteristics of Asian and non-Asian patients

Characteristic	Asian patients		Non-Asian patients		All patients	
	Crizotinib n=79	Chemotherapy ^{a)} n=78	Crizotinib n=94	Chemotherapy ^{a)} n=96	Crizotinib n=173	Chemotherapy ^{a)} n=174
PROFILE 1007						
Age (yr)						
Median	46	50	52	49	51	49
Range	24-75	24-85	22-81	26-79	22-81	24-85
Sex						
Male	31 (39)	33 (42)	44 (47)	45 (47)	75 (43)	78 (45)
Race ^{b)}						
Japanese	40 (51)	29 (37)	–	–	40 (23)	29 (17)
Korean	22 (28)	28 (36)	–	–	22 (13)	28 (16)
Chinese	14 (18)	18 (23)	–	–	14 (8)	18 (10)
Other Asian	3 (4)	3 (4)	–	–	3 (2)	3 (2)
Black	–	–	2 (2)	3 (3)	2 (1)	3 (2)
White	–	–	90 (96)	91 (95)	90 (52)	91 (52)
Other non-Asian	–	–	2 (2)	2 (2)	2 (1)	2 (1)
Smoking status ^{c)}						
Never	51 (65)	48 (62)	57 (61)	63 (66)	108 (62)	111 (64)
Former	28 (35)	28 (36)	31 (33)	26 (27)	59 (34)	54 (31)
Current	0	2 (3)	5 (5)	7 (7)	5 (3)	9 (5)
Not reported	0	0	1 (1)	0	1 (1)	0
Histology						
Adenocarcinoma	75 (95)	73 (94)	88 (94)	87 (91)	163 (94)	160 (92)
Non-adenocarcinoma	4 (5)	5 (6)	5 (5)	9 (10)	9 (5)	14 (8)
Not reported	0	0	1 (1)	0	1 (1)	0
ECOG PS ^{d)}						
0 or 1	74 (94)	74 (95)	80 (85)	85 (89)	154 (89)	159 (91)
2	5 (6)	4 (5)	14 (15)	11 (11)	19 (11)	15 (9)
Extent of disease						
Locally advanced	1 (1)	5 (6)	6 (6)	11 (11)	7 (4)	16 (9)
Metastatic	78 (99)	73 (94)	87 (93)	85 (89)	165 (95)	158 (91)
Not reported	0	0	1 (1)	0	1 (1)	0
Brain metastases present	36 (46)	27 (35)	24 (26)	33 (34)	60 (35)	60 (34)
Weight (kg)						
Median	56.5	58.1	69.0	73.3	62.0	63.3
Range	35-94	38-96	43-160	37-133	35-160	37-133

Characteristic	Asian patients		Non-Asian patients		All patients	
	Crizotinib	Chemotherapy ^{a)}	Crizotinib	Chemotherapy ^{a)}	Crizotinib	Chemotherapy ^{a)}
PROFILE 1014	n=77	n=80	n=95	n=91	n=172	n=171
Age (yr)						
Median	51	52	52	55	52	54
Range	25-76	19-76	22-76	19-78	22-76	19-78
Sex						
Male	35 (46)	27 (34)	33 (35)	36 (40)	68 (40)	63 (37)
Race ^{b)}						
Japanese	14 (18)	18 (23)	–	–	14 (8)	18 (11)
Korean	30 (39)	26 (33)	–	–	30 (17)	26 (15)
Chinese	27 (35)	32 (40)	–	–	27 (16)	32 (19)
Other Asian	6 (8)	4 (5)	–	–	6 (4)	4 (2)
Black	–	–	0	4 (4)	0	4 (2)
White	–	–	91 (96)	85 (93)	91 (53)	85 (50)
Other non-Asian	–	–	4 (4)	2 (2)	4 (2)	2 (1)
Smoking status						
Never	50 (65)	54 (68)	56 (59)	58 (64)	106 (62)	112 (66)
Former	26 (34)	25 (31)	30 (32)	29 (32)	56 (33)	54 (32)
Current	1 (1)	1 (1)	9 (10)	4 (4)	10 (6)	5 (3)
Histology						
Adenocarcinoma	72 (94)	74 (93)	89 (94)	87 (96)	161 (94)	161 (94)
Non-adenocarcinoma	5 (6)	6 (8)	6 (6)	4 (4)	11 (6)	10 (6)
ECOG PS						
0 or 1	75 (97)	78 (98)	86 (91)	85 (93)	161 (94)	163 (95)
2	2 (3)	2 (3)	8 (8)	6 (7)	10 (6)	8 (5)
Extent of disease						
Locally advanced	3 (4)	2 (3)	1 (1)	1 (1)	4 (2)	3 (2)
Metastatic	74 (96)	78 (98)	94 (99)	90 (99)	168 (98)	168 (98)
Brain metastases present	18 (23)	20 (25)	27 (28)	27 (30)	45 (26)	47 (27)
Weight (kg)						
Median	62.0	59.0	70.0	69.0	64.3	62.5
Range	43-86	40-83	43-118	36-152	43-118	36-152

Values are presented as number (%) unless otherwise indicated. ECOG PS, Eastern Cooperative Oncology Group performance status. ^{a)}PROFILE 1007: pemetrexed or docetaxel; PROFILE 1014: pemetrexed plus cisplatin or carboplatin, ^{b)}Race reported by investigators, ^{c)}Data are missing for one non-Asian patient in the crizotinib group of PROFILE 1007, ^{d)}At screening.